Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Acquisitions & Divestments (2016 - 2017)

Historic Change in Acquisitions & Divestments for Ocular Therapeutix (OCUL) over the last 3 years, with Q3 2017 value amounting to $3.0 million.

  • Ocular Therapeutix's Change in Acquisitions & Divestments fell 7956.96% to $3.0 million in Q3 2017 from the same period last year, while for Dec 2017 it was $38.2 million, marking a year-over-year decrease of 5265.48%. This contributed to the annual value of $38.2 million for FY2017, which is 5265.48% down from last year.
  • Ocular Therapeutix's Change in Acquisitions & Divestments amounted to $3.0 million in Q3 2017, which was down 7956.96% from $22.7 million recorded in Q2 2017.
  • Ocular Therapeutix's 5-year Change in Acquisitions & Divestments high stood at $30.0 million for Q3 2015, and its period low was $3.0 million during Q3 2017.
  • For the 3-year period, Ocular Therapeutix's Change in Acquisitions & Divestments averaged around $18.2 million, with its median value being $16.0 million (2016).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 666.67% in 2016, then tumbled by 7956.96% in 2017.
  • Ocular Therapeutix's Change in Acquisitions & Divestments (Quarter) stood at $15.0 million in 2015, then rose by 6.67% to $16.0 million in 2016, then crashed by 81.25% to $3.0 million in 2017.
  • Its last three reported values are $3.0 million in Q3 2017, $22.7 million for Q2 2017, and $12.5 million during Q1 2017.